AI Article Synopsis
- F-FP-DTBZ is a biomarker for measuring VMAT2 levels, which can help in assessing dopaminergic integrity in patients with Parkinson's disease (PD) compared to healthy controls, but its clinical use is not widespread yet.
- The study involved 34 PD patients and 31 healthy controls for the initial assessment, and 89 PD patients and 18 controls for validation, using PET/MR and PET/CT imaging.
- Results indicated that the contralateral posterior dorsal putamen (PDP) had the highest diagnostic accuracy for identifying PD, with an AUC of 0.973, demonstrating a very high sensitivity and specificity, thus supporting the use of FD-FP-DTBZ PET imaging for effective diagnosis
Article Abstract
Background: F-FP-DTBZ has been proven as a biomarker for quantifying the concentration of presynaptic vesicular monoamine transporter 2 (VMAT2). However, its clinical application is still limited.
Objectives: To evaluate the difference in dopaminergic integrity between patients with Parkinson's disease (PD) and healthy controls (HC) using F-FP-DTBZ PET and to determine the diagnostic value of standardized uptake value ratios (SUVRs) using the Receiver Operating Characteristic (ROC) curve.
Methods: A total of 34 PD and 31 HC participants were enrolled in the PET/MR derivation cohort, while 89 PD and 18 HC participants were recruited in the PET/CT validation cohort. The Hoehn-Yahr Scale and the third part of the MDS-Unified Parkinson's Disease Rating Scale (MDSUPDRS-III) were used to evaluate the disease staging and severity. All assessments and PET scanning were performed in drug-off states. The striatum was segmented into five subregions as follows: caudate, anterior dorsal putamen (ADP), anterior ventral putamen (AVP), posterior dorsal putamen (PDP), and posterior ventral putamen (PVP) using automatic pipeline built with the PMOD software (version 4.105). The SUVRs of the targeted subregions were calculated using the bilateral occipital cortex as the reference region.
Results: Regarding the diagnostic value, ROC curve and blind validation showed that the contralateral PDP (SUVR = 3.43) had the best diagnostic accuracy (AUC = 0.973; < 0.05), with a sensitivity of 97.1% (95% CI: 82.9-99.8%), specificity of 100% (95% CI: 86.3-100%), positive predictive value (PPV) of 100% (95% CI: 87.0-100%), negative predictive value (NPV) of 96.9% (95% CI: 82.0-99.8%), and an accuracy of 98.5% for the diagnosis of PD in the derivation cohort. Blind validation of F-FP-DTBZ PET imaging diagnosis was done using the PET/CT cohort, where participants with a SUVR of the PDP <3.43 were defined as PD. Kappa test showed a consistency of 0.933 ( < 0.05) between clinical diagnosis and imaging diagnosis, with a sensitivity of 98.9% (95% CI: 93.0-99.9%), specificity of 94.4% (95% CI: 70.6-99.7%), PPV of 98.9% (95% CI: 93.0-99.9%), NPV of 94.4% (95% CI: 70.6-99.7%), and a diagnostic accuracy of 98.1%.
Conclusions: Our results showed that an SUVR threshold of 3.43 in the PDP could effectively distinguish patients with PD from HC.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9355024 | PMC |
| http://dx.doi.org/10.3389/fnagi.2022.931015 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The combination of F-fluorodeoxyglucose and F 9-fluoropropyl-(+)-dihydrotetrabenazine positron emission tomography for distinguishing between early-onset and late-onset idiopathic Parkinson disease and analyzing influencing factors.
Quant Imaging Med Surg
October 2024
Department of Radiology and Nuclear Medicine, Xuanwu Hospital, Capital Medical University, Beijing, China.
Background: The classification of Parkinson disease by age of onset has proven to be a valuable method for subtyping, given its practical application in clinical settings. However, the interactions between the metabolic brain changes, dopaminergic dysfunction, and clinical manifestations in patients with early-onset (early-iPD) and late-onset (late-iPD) idiopathic Parkinson disease have not been adequately evaluated. Therefore, this study aimed to investigate the difference in cerebral metabolism and presynaptic dopaminergic function between patients with early-iPD and those with late-onset disease using F-fluorodeoxyglucose (F-FDG) and [F] 9-fluoropropyl-(+)-dihydrotetrabenazine (F-FP-DTBZ) positron emission tomography (PET).
View Article and Find Full Text PDFFirst-in-human study of D6-[F]FP-(+)-DTBZ, a novel VMAT2 tracer: whole-body biodistribution and brain PET comparison with [F]FP-(+)-DTBZ (AV-133).
EJNMMI Radiopharm Chem
October 2024
Department of Nuclear Medicine, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510120, Guangdong, China.
Article Synopsis
- D6-[F]FP-(+)-DTBZ is a new imaging agent designed for PET scans that helps diagnose Parkinson's disease (PD) by tracking VMAT2 transporters in the brain.
- In a study, this radioligand demonstrated efficient production, high purity, and distinct uptake in brain regions associated with PD, showing a greater effectiveness compared to its non-deuterated counterpart.
- The findings suggest that D6-[F]FP-(+)-DTBZ could serve as a safer, more effective tool for monitoring VMAT2 levels in monoamine neurons, potentially improving PD diagnosis.
Striatal and Extrastriatal Monoaminergic Disruption in Progressive Supranuclear Palsy.
Mov Disord
May 2024
Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, China.
Background: As a biomarker targeting vesicular monoamine transporter 2 (VMAT2), F-9-fluoropropyldihydrotetrabenazine (F-FP-DTBZ) positron emission tomography (PET) is highly accurate in diagnosing Parkinson's disease (PD) and assessing its severity. However, evidence is insufficient in patients with progressive supranuclear palsy (PSP).
Objective: We evaluated the striatal and extrastriatal monoaminergic disruption of PSP and differences in patterns between patients with PSP, PD, and healthy controls (HCs) using F-FP-DTBZ PET, as well as its correlations with the clinical characteristics of PSP.
F-FP-DTBZ PET/CT detectable associations between monoaminergic depletion in the putamen with rigidity and the pallidus with tremor in Parkinson's disease.
Parkinsonism Relat Disord
March 2024
Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, China. Electronic address:
Introduction: The motor subtypes of Parkinson's disease (PD) are widely accepted and implemented. However, the motor subtypes have been thought to represent different stages of PD recently because some patients experience tremor-dominant (TD) conversion to the non-tremor-dominant subtype, such as postural instability-gait difficulty (PIGD). In this study, we explore the monoaminergic denervation features of the striatal and extra-striatal areas in patients with different subtypes of PD with F-9-fluoropropyl-(+)-dihydrotetrabenazine (F-FP-DTBZ) PET/CT.
View Article and Find Full Text PDFNoninvasive Quantitative PET Imaging in Humans of the Pancreatic Beta-Cell Mass Biomarkers VMAT2 and Dopamine D2/D3 Receptors In Vivo.
Methods Mol Biol
December 2022
Department of Internal Medicine, Division of Endocrinology, Yale University School of Medicine, New Haven, CT, USA.
Noninvasive quantitative imaging of beta-cells can provide information on changes in cellular transporters, receptors, and signaling proteins that may affect function and/or loss of mass, both of which contribute to the loss of insulin secretion and glucose regulation of patients with type 1 or type 2 diabetes (T1D/T2D). We have developed and optimized the use of two positron emission tomography (PET) radioligands, [F]FP-(+)-DTBZ and [C](+)-PHNO, targeting beta-cell VMAT2 and dopamine (D2/D3) receptors, respectively. Here we describe our optimized methodology for the clinical use of these two tracers for quantitative PET imaging of beta-cell biomarkers in vivo.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!